Short Interest in Evogene Ltd. (NASDAQ:EVGN) Drops By 47.5%

Evogene Ltd. (NASDAQ:EVGN) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 71,600 shares, a decline of 47.5% from the February 29th total of 136,300 shares. Based on an average trading volume of 195,400 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Evogene

A number of large investors have recently bought and sold shares of EVGN. BNP Paribas Arbitrage SNC lifted its position in Evogene by 265.4% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 26,700 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 19,393 shares during the last quarter. Virtu Financial LLC acquired a new position in Evogene during the 1st quarter worth $48,000. Vident Investment Advisory LLC lifted its position in Evogene by 68.5% during the 1st quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 34,082 shares during the last quarter. Silverarc Capital Management LLC acquired a new position in Evogene during the 2nd quarter worth $107,000. Finally, Renaissance Technologies LLC lifted its position in Evogene by 31.8% during the 1st quarter. Renaissance Technologies LLC now owns 118,193 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 28,493 shares during the last quarter. 10.40% of the stock is currently owned by institutional investors.

Evogene Stock Performance

NASDAQ:EVGN remained flat at $0.74 during trading hours on Thursday. 58,664 shares of the company were exchanged, compared to its average volume of 193,536. The company has a market cap of $30.51 million, a P/E ratio of -1.40 and a beta of 1.50. Evogene has a 12-month low of $0.45 and a 12-month high of $1.44. The business has a 50 day moving average of $0.81 and a 200-day moving average of $0.72.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. The firm had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $1.73 million. Evogene had a negative net margin of 423.39% and a negative return on equity of 76.93%. During the same period in the prior year, the company posted ($0.07) earnings per share.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Evogene in a report on Monday, February 5th. They set a “sell” rating on the stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.